Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

658 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study.
Kakimi K, Matsushita H, Masuzawa K, Karasaki T, Kobayashi Y, Nagaoka K, Hosoi A, Ikemura S, Kitano K, Kawada I, Manabe T, Takehara T, Ebisudani T, Nagayama K, Nakamura Y, Suzuki R, Yasuda H, Sato M, Soejima K, Nakajima J. Kakimi K, et al. Among authors: soejima k. J Immunother Cancer. 2020 Sep;8(2):e001185. doi: 10.1136/jitc-2020-001185. J Immunother Cancer. 2020. PMID: 32948652 Free PMC article. Clinical Trial.
A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Yoda S, Soejima K, Yasuda H, Naoki K, Kawada I, Watanabe H, Nakachi I, Satomi R, Nakayama S, Ikemura S, Terai H, Sato T, Morosawa M, Asano K. Yoda S, et al. Among authors: soejima k. Cancer Chemother Pharmacol. 2011 Mar;67(3):717-22. doi: 10.1007/s00280-010-1539-y. Epub 2010 Dec 9. Cancer Chemother Pharmacol. 2011. PMID: 21152917 Clinical Trial.
Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.
Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, Naoki K, Matsumoto S, Mimaki S, Ikemura S, Goto K, Betsuyaku T, Soejima K. Nukaga S, et al. Among authors: soejima k. Cancer Res. 2017 Apr 15;77(8):2078-2089. doi: 10.1158/0008-5472.CAN-16-2359. Epub 2017 Feb 15. Cancer Res. 2017. PMID: 28202511
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A. Nakachi I, et al. Among authors: soejima k. Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20. Mol Cancer Res. 2010. PMID: 20647329
Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer.
Yoda S, Soejima K, Hamamoto J, Yasuda H, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Naoki K, Betsuyaku T. Yoda S, et al. Among authors: soejima k. Lung Cancer. 2014 Sep;85(3):366-72. doi: 10.1016/j.lungcan.2014.06.009. Epub 2014 Jun 21. Lung Cancer. 2014. PMID: 25001509
Methylation-induced downregulation of TFPI-2 causes TMPRSS4 overexpression and contributes to oncogenesis in a subset of non-small-cell lung carcinoma.
Hamamoto J, Soejima K, Naoki K, Yasuda H, Hayashi Y, Yoda S, Nakayama S, Satomi R, Terai H, Ikemura S, Sato T, Arai D, Ishioka K, Ohgino K, Betsuyaku T. Hamamoto J, et al. Among authors: soejima k. Cancer Sci. 2015 Jan;106(1):34-42. doi: 10.1111/cas.12569. Epub 2014 Dec 8. Cancer Sci. 2015. PMID: 25414083 Free PMC article.
658 results